A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.

Cancer Chemotherapy and Pharmacology
Cody J PeerWilliam D Figg

Abstract

Seviteronel is an orally-administered selective cytochrome P450c17a 17,20-lyase and androgen receptor inhibitor with anti-tumor activity in vitro and in vivo, and clinical activity in men with advanced castration-resistant prostate cancer (CRPC) and men and women with advanced breast cancer. The purpose of this study was to assess the pharmacokinetics (PK) of seviteronel across the aforementioned populations. This report describes the PK of seviteronel (50-750 mg, QD or BID) using noncompartmental and population approaches from 243 patients with advanced breast or prostate cancer pooled across 4 clinical studies. First dose and steady-state PK were examined, as well as covariates including prandial status, sex and concomitant dexamethasone. Seviteronel PK can be characterized by transit absorption and a bi-phasic first-order elimination while accounting for covariance between random effects. Prandial status did not significantly affect any parameters to a clinically-relevant extent. Both sex and body weight were significant covariates on clearance, explaining 37% of the interindividual variability on that parameter. There were no significant effects from the race or the presence of a corticosteroid (either dexamethasone or pred...Continue Reading

References

May 1, 1993·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·N KimuraH Nagura
Nov 4, 2000·Clinical Pharmacology and Therapeutics·J S McCuneC Lindley
Sep 27, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Renzo WolboldUlrich M Zanger
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Jul 27, 2007·Journal of Pharmacokinetics and Pharmacodynamics·Radojka M SavicMats O Karlsson
Aug 4, 2009·The AAPS Journal·Radojka M Savic, Mats O Karlsson
Oct 21, 2009·European Journal of Pharmacology·Salvador FudioJesús Frías
Jan 23, 2010·Breast Cancer Research and Treatment·Edith A PerezCathy A Andorfer
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Apr 30, 2014·Bioorganic & Medicinal Chemistry Letters·Stephen W RaffertyWilliam J Hoekstra
Jun 3, 2014·The New England Journal of Medicine·Tomasz M BeerUNKNOWN PREVAIL Investigators
Apr 5, 2016·Breast Cancer : Basic and Clinical Research·Simon B ZeichnerKeerthi Gogineni
Apr 8, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H BonnefoiA Gonçalves
May 15, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·X PivotA Wolfer
May 4, 2017·The Journal of Clinical Investigation·John D NorrisDonald P McDonnell
May 11, 2017·Journal of Oncology Practice·Ricardo L B Costa, William J Gradishar
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 27, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tiffany A TrainaJavier Cortes
Jul 18, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shilpa GuptaNeal D Shore

❮ Previous
Next ❯

Citations

Nov 3, 2020·Frontiers in Oncology·Daisuke ObinataSatoshi Inoue

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.